Loading clinical trials...
Loading clinical trials...
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
The purpose of this study is to collect medical informations and samples (blood, bone marrow and/or lymph node) from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms (BCL2 mutations, over-expression of other members of the BCL2 protein family and energy metabolism changes).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
CHU d'Amiens
Amiens, France
CHU de Besançon
Besançon, France
Hopital AVICENNE
Bobigny, France
CHU clermont-ferrand
Clermont-Ferrand, France
CHU de Clermont Ferrand
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
CHRU de Lille
Lille, France
Centre LEON BERARD
Lyon, France
CHU de Montpellier
Montpellier, France
CHU Nancy
Nancy, France
Start Date
March 7, 2022
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2027
Last Updated
January 9, 2024
50
ESTIMATED participants
Lead Sponsor
University Hospital, Clermont-Ferrand
NCT05006716
NCT07277231
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06859424